Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

NCT03334487 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03334487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03334487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Withdrawn
Start date
March 15, 2018
Completion date
December 20, 2018
Enrollment
0 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer